Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. Academic Article uri icon

Overview

abstract

  • There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.

publication date

  • September 30, 2022

Identity

PubMed Central ID

  • PMC9713049

Scopus Document Identifier

  • 85105205027

Digital Object Identifier (DOI)

  • 10.1038/s41408-021-00469-5

PubMed ID

  • 36467792

Additional Document Info

volume

  • 3

issue

  • 4